Questions? Feedback? powered by Olark live chat software

Nitric Oxide Signaling

Nitric oxide (NO) is an important signaling molecule of the nervous system. Signal transduction refers to the process of signaling between cells or other molecules in the cellular environment that occurs when a surface cell receptor is activated by a molecule, such as an antibody, creating a response. The resulting action then mediates a reaction within the cell through a second messenger which elicits the physiological response. Nitric oxide is synthesized by nitric oxide synthase (NOS). NO is a small, relatively unstable, free radical. There are three different isoforms of nitric oxide synthase. These include endothelial NOS, neuronal NOS, and inducible NOS. Nitric oxide is a messenger implicated in vasodilation neurotransmission, anti-tumor pathways, and anti-pathogenic activities. It is known primarily for maintaining normal blood pressure and blood flow to tissues. However, it can also expand narrow blood vessels to eliminate clots and reduce the risk of plaque formation; helps fight off infections, and kill cancer cells. Nitric oxide is unique in that it is necessary for many bodily functions, but also toxic to most bodily tissues in direct and sustained amounts. Nitric oxide is present in cigarette smoke, motorcar exhaust, and acid rain.

Anti-GTP cyclohydrolase 1 antibody binds against the target GTP cyclohydrolase 1 (GCH1). GTP cyclohydrolase is an enzyme localized in the cytoplasm and in the nucleus. CGH1 is localized in the epidermis. GTP cyclohydrolase 1 positively regulates nitric oxide synthesis in umbilical vein endothelial cells and may be involved in dopamine synthesis. Defects in GCH1 are the cause of GTP cyclohydrolase 1 deficiency and dystonia type 5. GTP cyclohydrolase 1 deficiency (otherwise known as Segawa Syndrome) is a genetic disorder that can cause physical rigidity and developmental delay. Dystonia type 5, or dopamine responsive dystonia, is a neurological movement disorder characterized by sustained muscle contractions that cause twisting and repetitive movements or abnormal postures. Treatment for dystonia type 5 is the use of L-dopa. Anti-CAPON antibody binds against the adapter protein nitric oxide synthase 1. CAPON is involved in neuronal nitric-oxide synthesis regulation. CAPON mediates an indirect interaction between NOS1 and RASD11 leading to the enhanced ability of NOS1 to activate RASD1.

 
Product Number Title Applications Host Clonality
AC21-0105-01 Anti-nNOS Antibody (AMCA) ELISA, WB, IF, IHC Goat Polyclonal
AC21-0105-02 Anti-nNOS Antibody (AP) ELISA, WB, IF, IHC Goat Polyclonal
AC21-0105-03 Anti-nNOS Antibody (APC) ELISA, WB, IF, IHC Goat Polyclonal
AC21-0105-04 Anti-nNOS Antibody (APC-Cy5.5) ELISA, WB, IF, IHC Goat Polyclonal
AC21-0105-05 Anti-nNOS Antibody (APC-Cy7) ELISA, WB, IF, IHC Goat Polyclonal
AC21-0105-06 Anti-nNOS Antibody (Avidin) ELISA, WB, IF, IHC Goat Polyclonal
AC21-0105-07 Anti-nNOS Antibody (Biotin) ELISA, WB, IF, IHC Goat Polyclonal
AC21-0105-08 Anti-nNOS Antibody (BPE) ELISA, WB, IF, IHC Goat Polyclonal
AC21-0105-09 Anti-nNOS Antibody (Cy3) ELISA, WB, IF, IHC Goat Polyclonal
AC21-0105-10 Anti-nNOS Antibody (Cy5) ELISA, WB, IF, IHC Goat Polyclonal
AC21-0105-11 Anti-nNOS Antibody (Cy5.5) ELISA, WB, IF, IHC Goat Polyclonal
AC21-0105-12 Anti-nNOS Antibody (FITC) ELISA, WB, IF, IHC Goat Polyclonal